AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28449601 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice
Number of subjects: 30
Study 28449601 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked practice
Number of subjects: 30
Study 28449601 — intervention group
Group type: COMPARATOR
Intervention: No-practice
Number of subjects: 30
Study 26188109 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-5334 (100mg slow-release tablets)
Number of subjects: 10
Study 23386568 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track prevention program
Number of subjects: 891
Study 23386568 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial aggressive-disruptive behaviors and associated school readiness skills (cognitive ability, reading readiness, attention problems)
Number of subjects: 891
Study 22108107 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet (UV) and blue light-filtering IOL (Acrysof Natural SN60AT)
Number of subjects: 30
Study 22108107 — intervention group
Group type: COMPARATOR
Intervention: Acrylic UV light-filtering only IOL (Acrysof SA60AT)
Number of subjects: 30
Study 19426750 — intervention group
Group type: EXPERIMENTAL
Intervention: 3rd derivative spatial filtering
Number of subjects: 0
Study 19426750 — intervention group
Group type: COMPARATOR
Intervention: Standard edge-detection schemes
Number of subjects: 0
Study 16792148 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylometazoline
Number of subjects: 0
Study 16792148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15460628 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg at 7.5 h, 100 mg at 3 h, and 100 mg at 0 h)
Number of subjects: 20
Study 15460628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11248619 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium:yttrium‐aluminum‐garnet laser resection of the prostate (HoLRP)
Number of subjects: 120
Study 11248619 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 120
Study 9137222 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week moderate intensity supervised hospital-based exercise training program
Number of subjects: 49
Study 9137222 — intervention group
Group type: COMPARATOR
Intervention: unsupervised low intensity home walking program (control group)
Number of subjects: 49
Study 9137222 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined outcomes for both groups
Number of subjects: 49
Study 8187119 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 20 mg/day (n = 54)
Number of subjects: 115
Study 8187119 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 53)
Number of subjects: 115
Study 2976110 — intervention group
Group type: COMPARATOR
Intervention: Atrial natriuretic peptide (ANP) 150 μg over 30 minutes (protocol 1)
Number of subjects: 17
Study 2976110 — intervention group
Group type: COMPARATOR
Intervention: Atrial natriuretic peptide (ANP) 200 μg over 30 minutes (protocol 2)
Number of subjects: 17
Study 31822212 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-month multicomponent intervention program
Number of subjects: 30
Study 30808293 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftobiprole
Number of subjects: 705
Study 28279368 — intervention group
Group type: EXPERIMENTAL
Intervention: Care guided by advanced echocardiography (myocardial deformation and detailed diastolic function)
Number of subjects: 618
Study 28279368 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 618
Study 28279368 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging-guided care
Number of subjects: 618
Study 26232545 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated whole‐cell cholera vaccine (Shanchol), 2 doses
Number of subjects: 123661
Study 26232545 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated whole‐cell cholera vaccine (Shanchol), 1 dose
Number of subjects: 123661
Study 23680937 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal isokinetic eccentric resistance training (IERT) knee extensor actions at 180° s(‐1) for 8 weeks
Number of subjects: 20
Study 23680937 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 21458153 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil 50mg once daily for 12 weeks
Number of subjects: 237
Study 21458153 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil 75mg once daily for 12 weeks
Number of subjects: 237
Study 21458153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 18972724 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy after electroacupuncture (EA)
Number of subjects: 0
Study 18972724 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture (EA) after exercise therapy
Number of subjects: 0
Study 16484135 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Cigarettes (CC1)
Number of subjects: 110
Study 16484135 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-tar Conventional Cigarettes (CC2)
Number of subjects: 110
Study 16484135 — intervention group
Group type: EXPERIMENTAL
Intervention: EHCSS1
Number of subjects: 110
Study 16484135 — intervention group
Group type: EXPERIMENTAL
Intervention: EHCSS2
Number of subjects: 110
Study 16484135 — intervention group
Group type: COMPARATOR
Intervention: No Smoking
Number of subjects: 110
Study 12955293 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 0
Study 12955293 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.3 or 0.5 mg SC)
Number of subjects: 0
Study 12955293 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 10832598 — intervention group
Group type: EXPERIMENTAL
Intervention: NK cell counts
Number of subjects: 235
Study 10832598 — intervention group
Group type: EXPERIMENTAL
Intervention: beta2‐microglobulin
Number of subjects: 235
Study 10832598 — intervention group
Group type: EXPERIMENTAL
Intervention: sIL‐2r serum levels
Number of subjects: 235
Study 10832598 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune cell counts and markers of activation
Number of subjects: 235
Study 9199941 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole‐echocardiography test (DET)
Number of subjects: 547
Study 9199941 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise electrocardiography test (EET)
Number of subjects: 547
Study 9199941 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 547
Study 8222773 — intervention group
Group type: EXPERIMENTAL
Intervention: Tromantadine ointment 1%
Number of subjects: 45
Study 8222773 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ointment base alone)
Number of subjects: 45
Study 3302150 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 551
Study 3302150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study 31860981 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine at 4 μg/minute
Number of subjects: 97
Study 29517802 — intervention group
Group type: EXPERIMENTAL
Intervention: WellWe intervention
Number of subjects: 200
Study 29517802 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 26761520 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP use disclosure
Number of subjects: 1395
Study 26761520 — intervention group
Group type: EXPERIMENTAL
Intervention: Undetectable viral load (UVL) disclosure
Number of subjects: 1395
Study 26761520 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated risk assessment for CAS
Number of subjects: 1395
Study 26761520 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomed-matching strategy
Number of subjects: 1395
Study 24835623 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage arthroplasty
Number of subjects: 248
Study 24835623 — intervention group
Group type: COMPARATOR
Intervention: Internal fixation (control)
Number of subjects: 248
Study 22846250 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive telephone counseling
Number of subjects: 0
Study 22846250 — intervention group
Group type: COMPARATOR
Intervention: Nondirective telephone counseling
Number of subjects: 0
Study 19525241 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching (30 s static stretches of seven lower limb and trunk muscle groups before and after physical activity for 12 weeks)
Number of subjects: 2377
Study 19525241 — intervention group
Group type: COMPARATOR
Intervention: Control (no stretching)
Number of subjects: 2377
Study 18700421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cidofovir
Number of subjects: 19
Study 18700421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 16459894 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit Association Test (IAT)
Number of subjects: 0
Study 12671031 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day for 4 weeks)
Number of subjects: 10
Study 10227557 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous force application (100 g tipping force, elastics worn 24 hours per day)
Number of subjects: 22
Study 10227557 — intervention group
Group type: COMPARATOR
Intervention: Discontinuous force application (100 g tipping force, elastics worn 12 hours per day)
Number of subjects: 22
Study 8912962 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% C3F8
Number of subjects: 149
Study 8912962 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% C3F8
Number of subjects: 149
Study 8912962 — intervention group
Group type: EXPERIMENTAL
Intervention: 16% C3F8
Number of subjects: 149
Study 8256911 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral cold dry air (UniCDA) nasal challenge
Number of subjects: 0
Study 8256911 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical atropine (0.225 mg) given ipsilateral to UniCDA
Number of subjects: 0
Study 8256911 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical atropine given contralateral to UniCDA
Number of subjects: 0
Study 8256911 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia with lidocaine given ipsilateral to UniCDA
Number of subjects: 0
Study 8256911 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia with lidocaine
Number of subjects: 0
Study 2951875 — intervention group
Group type: EXPERIMENTAL
Intervention: emiglitate
Number of subjects: 10
Study 2951875 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 31581959 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (1400 mg/day of EPA and DHA)
Number of subjects: 271
Study 31581959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 29644990 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction technique
Number of subjects: 72
Study 29644990 — intervention group
Group type: COMPARATOR
Intervention: EMLA (anaesthetic cream)
Number of subjects: 72
Study 29644990 — intervention group
Group type: COMPARATOR
Intervention: Distraction technique vs EMLA
Number of subjects: 72
Study 27799236 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin
Number of subjects: 72
Study 24951881 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based methotrexate self-injection education video (12 minutes) followed by in-person nurse education
Number of subjects: 29
Study 24951881 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based methotrexate self-injection education video
Number of subjects: 29
Study 24951881 — intervention group
Group type: COMPARATOR
Intervention: Standard nurse-led teaching
Number of subjects: 29
Study 23398978 — intervention group
Group type: EXPERIMENTAL
Intervention: Group follow-up after DAFNE education
Number of subjects: 437
Study 23398978 — intervention group
Group type: COMPARATOR
Intervention: Individual clinic visits after DAFNE education
Number of subjects: 437
Study 19430987 — intervention group
Group type: EXPERIMENTAL
Intervention: Kabat's rehabilitation (proprioceptive neuromuscular rehabilitation)
Number of subjects: 20
Study 19430987 — intervention group
Group type: COMPARATOR
Intervention: Non-rehabilitated patients
Number of subjects: 20
Study 18248533 — intervention group
Group type: EXPERIMENTAL
Intervention: Explosive-type heavy-resistance training (75-80% of 1 repetition maximum) for 12 weeks
Number of subjects: 2
Study 16651507 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention program
Number of subjects: 441
Study 16651507 — intervention group
Group type: COMPARATOR
Intervention: Continued care as usual
Number of subjects: 441
Study 12504167 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of linoleic acid (15 g/day)
Number of subjects: 30
Study 12504167 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate dose of linoleic acid (7.5 g/day)
Number of subjects: 30
Study 12504167 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 g palmitic acid/day)
Number of subjects: 30
Study 12504167 — intervention group
Group type: EXPERIMENTAL
Intervention: All experimental groups (high and intermediate linoleic acid and control)
Number of subjects: 30
Study 12504167 — intervention group
Group type: EXPERIMENTAL
Intervention: All experimental groups
Number of subjects: 30
Study 10077397 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (Q-Gel) 60 mg twice daily
Number of subjects: 47
Study 10077397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 10077397 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (Q-Gel)
Number of subjects: 47
Study 7655127 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase 2.5 mg once daily
Number of subjects: 968
Study 7655127 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase 2.5 mg twice daily
Number of subjects: 968
Study 7655127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 968
Study 2679960 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradurin, 160 mg per month
Number of subjects: 0
Study 2679960 — intervention group
Group type: COMPARATOR
Intervention: Bilateral orchiectomy
Number of subjects: 0
Study 1255641 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 5% ethanol in 5% dextrose/water according to a weight‐time‐dose schedule
Number of subjects: 0
Study 1255641 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 31423685 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 210
Study 31423685 — intervention group
Group type: COMPARATOR
Intervention: Degludec (50 U)
Number of subjects: 210
Study 29050397 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (25 mg, 50 mg, 150 mg, 300 mg, once daily for 8 weeks)
Number of subjects: 26
Study 29050397 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once daily for 8 weeks)
Number of subjects: 26
Study 25033102 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES) in chronic total occlusions (CTO)
Number of subjects: 3589
Study 25033102 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES) in non-chronic total occlusions (TO)
Number of subjects: 3589
Study 25033102 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES) in non-occluded lesions
Number of subjects: 3589
Study 25033102 — intervention group
Group type: COMPARATOR
Intervention: Resolute zotarolimus-eluting stent (R-ZES) in total occlusions (TO)
Number of subjects: 3589
Study 24308224 — intervention group
Group type: EXPERIMENTAL
Intervention: Online hemodiafiltration (OLHDF)
Number of subjects: 85
Study 24308224 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis (HD)
Number of subjects: 85
Study 20602263 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg intravenous
Number of subjects: 89
Study 20602263 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (control)
Number of subjects: 89
Study 20602263 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron
Number of subjects: 89
Study 19485818 — intervention group
Group type: EXPERIMENTAL
Intervention: CRx-102 (combination of dipyridamole and prednisolone)
Number of subjects: 57
Study 19485818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 16401678 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral family systems therapy for diabetes (BFST-D)
Number of subjects: 104
Study 16401678 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational support group (ES)
Number of subjects: 104
Study 16401678 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 104
Study 15223987 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical inactivity
Number of subjects: 6705
Study 11068213 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote superficial femoral artery endarterectomy (RSFE)
Number of subjects: 50
Study 11068213 — intervention group
Group type: COMPARATOR
Intervention: In situ vein bypass
Number of subjects: 50
Study 9261322 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.05% proparacaine
Number of subjects: 34
Study 9261322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 8173900 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical assessment of sepsis in the intersphincteric space
Number of subjects: 22
Study 8173900 — intervention group
Group type: COMPARATOR
Intervention: Microbiological analysis (culture of gut organisms)
Number of subjects: 22
Study 3296669 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol
Number of subjects: 9
Study 3296669 — intervention group
Group type: COMPARATOR
Intervention: Mixed meal alone
Number of subjects: 9
Study 3296669 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol and sucrose
Number of subjects: 9
Study 3296669 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 9
Study 3296669 — intervention group
Group type: EXPERIMENTAL
Intervention: All solid meals
Number of subjects: 9
Study 28530142 — intervention group
Group type: EXPERIMENTAL
Intervention: TargetEd MAnageMent Intervention (TEAM)
Number of subjects: 38
Study 28530142 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 38
Study 28475123 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 0
Study 28475123 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT
Number of subjects: 0
Study 25369906 — intervention group
Group type: EXPERIMENTAL
Intervention: In-Home Cognitive Behavioral Therapy (IH-CBT) plus home visiting
Number of subjects: 93
Study 25369906 — intervention group
Group type: COMPARATOR
Intervention: Standard home visiting (SHV)
Number of subjects: 93
Study 25369906 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IH-CBT and SHV)
Number of subjects: 93
Study 24219054 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-hypertensive treatment
Number of subjects: 788
Study 24219054 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients
Number of subjects: 788
Study 24219054 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 788
Study 24219054 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and 1 year assessment
Number of subjects: 788
Study 21345781 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin administration (150 to 325 mg) within 6 hours postoperatively
Number of subjects: 200
Study 21345781 — intervention group
Group type: COMPARATOR
Intervention: Non-administration of aspirin
Number of subjects: 200
Study 18492840 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (1.4 g.kg(‐1).d(‐1) protein and 3 daily servings of dairy)
Number of subjects: 130
Study 18492840 — intervention group
Group type: COMPARATOR
Intervention: Conventional high-carbohydrate diet (0.8 g.kg(‐1).d(‐1) protein and 2 daily servings of dairy)
Number of subjects: 130
Study 17140522 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART) without local analgesia (LA)
Number of subjects: 300
Study 17140522 — intervention group
Group type: COMPARATOR
Intervention: Conventional restorative method without local analgesia (LA)
Number of subjects: 300
Study 17140522 — intervention group
Group type: COMPARATOR
Intervention: Conventional restorative method with local analgesia (LA)
Number of subjects: 300
Study 14574650 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group received assessment, case management, and referral to appropriate resources.
Number of subjects: 188
Study 14574650 — intervention group
Group type: COMPARATOR
Intervention: Control group given a list of services.
Number of subjects: 188
Study 14574650 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (case management model).
Number of subjects: 188
Study 11015798 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine administered to 60 children with 162 household contacts
Number of subjects: 149
Study 11015798 — intervention group
Group type: COMPARATOR
Intervention: Control group received hepatitis A vaccine administered to 67 age-matched children with 166 household contacts
Number of subjects: 149
Study 11015798 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination for school-aged household contacts (aged 5-17 years)
Number of subjects: 149
Study 9001837 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxatidine 150 mg once nightly
Number of subjects: 192
Study 9001837 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg once nightly
Number of subjects: 192
Study 1293305 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5‐10 mg once daily (n = 21)
Number of subjects: 41
Study 1293305 — intervention group
Group type: COMPARATOR
Intervention: Captopril 25‐50 mg twice daily (n = 20)
Number of subjects: 41
Study 1293305 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5‐10 mg once daily
Number of subjects: 41
Study 1293305 — intervention group
Group type: COMPARATOR
Intervention: Captopril 25‐50 mg twice daily
Number of subjects: 41
Study 6336983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural administration of 500 mg of tetracycline in solution (pH = 2.8)
Number of subjects: 30
Study 6336983 — intervention group
Group type: COMPARATOR
Intervention: Control group (solution of similar pH and appearance)
Number of subjects: 30
Study 30392584 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple Watch (Apple Inc, Cupertino, CA) for detecting irregular pulse
Number of subjects: 419093